NCT04819841 - Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 15, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions

Sickle Cell Disease

Interventions

GENETIC

nula-cel Drug Product

nula-cel is administered via IV infusion following a myeloablative conditioning regimen

Trial Locations (3)

NOT_YET_RECRUITING

Nationwide Children's Hospital, Columbus

RECRUITING

Washington University, St Louis

RECRUITING

Lucile Packard Children's Hospital, Palo Alto